Animal models used in the research of nanoparticles for cardiovascular diseases

1. Ahmed SM, Abdelrahman SA, Salama AE (2017) Efficacy of gold nanoparticles against isoproterenol induced acute myocardial infarction in adult male albino rats. Ultrastruct Pathol. 41(2):168–18510.1080/01913123.2017.1281367 ↗

2. Bae S, Park M, Kang C, Dilmen S, Kang TH, Kang DG, Ke Q, Lee SU, Lee D, Kang PM (2016) Hydrogen peroxide-responsive nanoparticle reduces myocardial ischemia/reperfusion injury. J Am Heart Assoc 5(11):e00369710.1161/JAHA.116.003697 ↗

3. Beg S, Sharma G, Thanki K, Jain S, Katare OP, Singh B (2015) Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: systematic development, in vitro, ex vivo and in vivo evaluation. Int J Pharm. 493(1-2):466–48210.1016/j.ijpharm.2015.07.048 ↗

4. Cannata A, Ali H, Sinagra G, Giacca M (2020) Gene therapy for the heart lessons learned and future perspectives. Circ Res. 126(10):1394–141410.1161/CIRCRESAHA.120.315855 ↗

5. Chadha R, Bhandari S, Kataria D, Gupta S, Singh JD (2012) Exploring the potential of lecithin/chitosan nanoparticles in enhancement of antihypertensive efficacy of hydrochlorothiazide. J Microencapsul. 29(8):805–81210.3109/02652048.2012.692399 ↗

6. Chang MY, Yang YJ, Chang CH, Tang ACL, Liao WY, Cheng FY, Yeh CS, Lai JJ, Stayton PS, Hsieh PCH (2013) Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction. J Control Release. 170(2):287–29410.1016/j.jconrel.2013.04.022 ↗

7. Dong C, Ma A, Shang L (2018) Nanoparticles for postinfarct ventricular remodeling. Nanomedicine (Lond). 13(23):3037–305010.2217/nnm-2018-0264 ↗

8. Doris PA (2017) Genetics of hypertension: an assessment of progress in the spontaneously hypertensive rat. Physiol Genomics. 49(11):601–61710.1152/physiolgenomics.00065.2017 ↗

9. El Shaer SS, Salaheldin TA, Saied NM, Abdelazim SM (2017) In vivo ameliorative effect of cerium oxide nanoparticles in isoproterenol-induced cardiac toxicity. Exp Toxicol Pathol. 69(7):435–44110.1016/j.etp.2017.03.001 ↗

10. Fan C, Oduk Y, Zhao M, Lou X, Tang Y, Pretorius D, Valarmathi MT, Walcott GP, Yang J, Menasche P, Krishnamurthy P, Zhu W, Zhang J (2020) Myocardial protection by nanomaterials formulated with CHIR99021 and FGF1. JCI Insight 5(12):e13279610.1172/jci.insight.132796 ↗

11. Fu H, Li X, Tan J (2018) NIPAAm-MMA nanoparticle-encapsulated visnagin ameliorates myocardial ischemia/reperfusion injury through the promotion of autophagy and the inhibition of apoptosis. Oncol Lett. 15(4):4827–4836

12. Galagudza M, Korolev D, Postnov V, Naumisheva E, Grigorova Y, Uskov I, Shlyakhto E (2012) Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles. Int J Nanomedicine. 7:1671–167810.2147/IJN.S29511 ↗

13. Hardy N, Viola HM, Johnstone VP et al (2015) Nanoparticle-mediated dual delivery of an antioxidant and a peptide against the L-Type Ca2+ channel enables simultaneous reduction of cardiac ischemia-reperfusion injury. ACS Nano. 9(1):279–28910.1021/nn5061404 ↗

14. Herrera VL, Colby AH, Ruiz-Opazo N, Coleman DG, Grinstaff MW (2018) Nucleic acid nanomedicines in Phase II/III clinical trials: translation of nucleic acid therapies for reprogramming cells. Nanomedicine (Lond). 13(16):2083–209810.2217/nnm-2018-0122 ↗

15. Holland NA, Becak DP, Shannahan JH, Brown JM, Carratt SA, Winkle L, Pinkerton KE, Wang CM, Munusamy P, Baer DR, Sumner SJ, Fennell TR, Lust RM, Wingard CJ (2015) Cardiac ischemia reperfusion injury following instillation of 20 nm citrate-capped nanosilver. J Nanomed Nanotechnol 6:00610.4172/2157-7439.S6-006 ↗

16. Ichimura K, Matoba T, Nakano K, Tokutome M, Honda K, Koga JI, Egashira K (2016) A translational study of a new therapeutic approach for acute myocardial infarction: nanoparticle-mediated delivery of pitavastatin into reperfused myocardium reduces ischemia-reperfusion injury in a preclinical porcine model. PLoS One. 11(9):e016242510.1371/journal.pone.0162425 ↗

17. Ikeda G, Matoba T, Nakano Y, Nagaoka K, Ishikita A, Nakano K, Funamoto D, Sunagawa K, Egashira K (2016) Nanoparticle-mediated targeting of cyclosporine A enhances cardioprotection against ischemia-reperfusion injury through inhibition of mitochondrial permeability transition pore opening. Sci Rep. 6:2046710.1038/srep20467 ↗

18. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J (1993) Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 92(2):883–89310.1172/JCI116663 ↗

19. Ishihara T, Hayashi E, Yamamoto S, Kobayashi C, Tamura Y, Sawazaki R, Tamura F, Tahara K, Kasahara T, Ishihara T, Takenaga M, Fukuda K, Mizushima T (2015) Encapsulation of beraprost sodium in nanoparticles: analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension. J Control Release. 197:97–10410.1016/j.jconrel.2014.10.029 ↗

20. Ishikita A, Matoba T, Ikeda G, Koga J, Mao Y, Nakano K, Takeuchi O, Sadoshima J, Egashira K (2016) Nanoparticle-mediated delivery of mitochondrial division inhibitor 1 to the myocardium protects the heart from ischemia-reperfusion injury through inhibition of mitochondria outer membrane permeabilization: a new therapeutic modality for acute myocardial infarction. J Am Heart Assoc 5(7):e00387210.1161/JAHA.116.003872 ↗

21. Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, Mente A, Yusuf S (2017) Reducing the global burden of cardiovascular disease, Part 1: the epidemiology and risk factors. Circ Res. 121(6):677–69410.1161/CIRCRESAHA.117.308903 ↗

22. Kim YI, Fluckiger L, Hoffman M, Lartaud-Idjouadiene I, Atkinson J, Maincent P (1997) The antihypertensive effect of orally administered nifedipine-loaded nanoparticles in spontaneously hypertensive rats. Br J Pharmacol. 120(3):399–40410.1038/sj.bjp.0700910 ↗

23. Klein AV, Kiat H (2015) The mechanisms underlying fructose-induced hypertension: a review. J Hypertens. 33(5):912–92010.1097/HJH.0000000000000551 ↗

24. Lejay A, Fang F, John R, van JAD, Barr M, Thaveau F, Chakfe N, Geny B, Scholey JW (2016) Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus. J Mol Cell Cardiol. 91:11–2210.1016/j.yjmcc.2015.12.020 ↗

25. Leong DP, Joseph PG, McKee M, Anand SS, Teo KK, Schwalm JD, Yusuf S (2017) Reducing the global burden of cardiovascular disease, Part 2: prevention and treatment of cardiovascular disease. Circ Res. 121(6):695–71010.1161/CIRCRESAHA.117.311849 ↗

26. Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, Lee KM, Kim JI, Markmann JF, Marinelli B, Panizzi P, Lee WW, Iwamoto Y, Milstein S, Epstein-Barash H, Cantley W, Wong J, Cortez-Retamozo V, Newton A, Love K, Libby P, Pittet MJ, Swirski FK, Koteliansky V, Langer R, Weissleder R, Anderson DG, Nahrendorf M (2011) Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol. 29(11):1005–101010.1038/nbt.1989 ↗

27. Lundy DJ, Chen KH, Toh EK, Hsieh PC (2016) Distribution of systemically administered nanoparticles reveals a size-dependent effect immediately following cardiac ischaemia-reperfusion injury. Sci Rep. 6:2561310.1038/srep25613 ↗

28. Mao Y, Koga JI, Tokutome M, Matoba T, Ikeda G, Nakano K, Egashira K (2017) Nanoparticle-mediated delivery of pitavastatin to monocytes/macrophages inhibits left ventricular remodeling after acute myocardial infarction by inhibiting monocyte-mediated inflammation. Int Heart J. 58(4):615–62310.1536/ihj.16-457 ↗

29. Maranhao RC, Guido MC, de Lima AD et al (2017) Methotrexate carried in lipid core nanoparticles reduces myocardial infarction size and improves cardiac function in rats. Int J Nanomedicine. 12:3767–378410.2147/IJN.S129324 ↗

30. Matuszak J, Lutz B, Sekita A, Zaloga J, Alexiou C, Lyer S, Cicha I (2018) Drug delivery to atherosclerotic plaques using superparamagnetic iron oxide nanoparticles. Int J Nanomedicine. 13:8443–846010.2147/IJN.S179273 ↗

31. Meneghini BC, Tavares ER, Guido MC, Tavoni TM, Stefani HA, Kalil-Filho R, Maranhão RC (2019) Lipid core nanoparticles as vehicle for docetaxel reduces atherosclerotic lesion, inflammation, cell death and proliferation in an atherosclerosis rabbit model. Vascul Pharmacol. 115:46–5410.1016/j.vph.2019.02.003 ↗

32. Nabofa WEE, Alashe OO, Oyeyemi OT, Attah AF, Oyagbemi AA, Omobowale TO, Adedapo AA, Alada ARA (2018) Cardioprotective effects of curcumin-nisin based poly lactic acid nanoparticle on myocardial infarction in guinea pigs. Sci Rep. 8(1):1664910.1038/s41598-018-35145-5 ↗

33. Nagaoka K, Matoba T, Mao Y, Nakano Y, Ikeda G, Egusa S, Tokutome M, Nagahama R, Nakano K, Sunagawa K, Egashira K (2015) A new therapeutic modality for acute myocardial infarction: nanoparticle-mediated delivery of pitavastatin induces cardioprotection from ischemia-reperfusion injury via activation of PI3K/Akt pathway and anti-inflammation in a rat model. PLoS One. 10(7):e013245110.1371/journal.pone.0132451 ↗

34. Nakano Y, Matoba T, Tokutome M, Funamoto D, Katsuki S, Ikeda G, Nagaoka K, Ishikita A, Nakano K, Koga JI, Sunagawa K, Egashira K (2016) Nanoparticle-mediated delivery of irbesartan induces cardioprotection from myocardial ischemia-reperfusion injury by antagonizing monocyte-mediated inflammation. Sci Rep. 6:2960110.1038/srep29601 ↗

35. No Author (2020) Nanomedicine and the COVID-19 vaccines. Nat Nanotechnol 15(12):96310.1038/s41565-020-00820-0 ↗

36. Pechanova O, Barta A, Koneracka M, Zavisova V, Kubovcikova M, Klimentova J, Trk J, Zemancikova A, Cebova M (2019) Protective effects of nanoparticle-loaded aliskiren on cardiovascular system in spontaneously hypertensive rats. Molecules 24(15):271010.3390/molecules24152710 ↗

37. Ranpise NS, Korabu SS, Ghodake VN (2014) Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf B Biointerfaces. 116:81–8710.1016/j.colsurfb.2013.12.012 ↗

38. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V, Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton A, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis JR, Catapano AL, Chugh S, Cooper LT, Coresh J, Criqui MH, DeCleene NK, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Sola J, Fowkes FGR, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum NJ, Koroshetz WJ, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Misganaw AT, Mokdad AH, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Oliveira GMM, Otto CM, Owolabi MO, Pratt M, Rajagopalan S, Reitsma MB, Ribeiro ALP, Rigotti NA, Rodgers A, Sable CA, Shakil SS, Sliwa K, Stark BA, Sundström J, Timpel P, Tleyjeh II, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke LJ, Abbasi-Kangevari M, Abdi A, Abedi A, Aboyans V, Abrha WA, Abu-Gharbieh E, Abushouk AI, Acharya D, Adair T, Adebayo OM, Ademi Z, Advani SM, Afshari K, Afshin A, Agarwal G, Agasthi P, Ahmad S, Ahmadi S, Ahmed MB, Aji B, Akalu Y, Akande-Sholabi W, Aklilu A, Akunna CJ, Alahdab F, al-Eyadhy A, Alhabib KF, Alif SM, Alipour V, Aljunid SM, Alla F, Almasi-Hashiani A, Almustanyir S, al-Raddadi RM, Amegah AK, Amini S, Aminorroaya A, Amu H, Amugsi DA, Ancuceanu R, Anderlini D, Andrei T, Andrei CL, Ansari-Moghaddam A, Anteneh ZA, Antonazzo IC, Antony B, Anwer R, Appiah LT, Arabloo J, Ärnlöv J, Artanti KD, Ataro Z, Ausloos M, Avila-Burgos L, Awan AT, Awoke MA, Ayele HT, Ayza MA, Azari S, B DB, Baheiraei N, Baig AA, Bakhtiari A, Banach M, Banik PC, Baptista EA, Barboza MA, Barua L, Basu S, Bedi N, Béjot Y, Bennett DA, Bensenor IM, Berman AE, Bezabih YM, Bhagavathula AS, Bhaskar S, Bhattacharyya K, Bijani A, Bikbov B, Birhanu MM, Boloor A, Brant LC, Brenner H, Briko NI, Butt ZA, Caetano dos Santos FL, Cahill LE, Cahuana-Hurtado L, Cámera LA, Campos-Nonato IR, Cantu-Brito C, Car J, Carrero JJ, Carvalho F, Castañeda-Orjuela CA, Catalá-López F, Cerin E, Charan J, Chattu VK, Chen S, Chin KL, Choi JYJ, Chu DT, Chung SC, Cirillo M, Coffey S, Conti S, Costa VM, Cundiff DK, Dadras O, Dagnew B, Dai X, Damasceno AAM, Dandona L, Dandona R, Davletov K, de la Cruz-Góngora V, de la Hoz FP, de Neve JW, Denova-Gutiérrez E, Derbew Molla M, Derseh BT, Desai R, Deuschl G, Dharmaratne SD, Dhimal M, Dhungana RR, Dianatinasab M, Diaz D, Djalalinia S, Dokova K, Douiri A, Duncan BB, Duraes AR, Eagan AW, Ebtehaj S, Eftekhari A, Eftekharzadeh S, Ekholuenetale M, el Nahas N, Elgendy IY, Elhadi M, el-Jaafary SI, Esteghamati S, Etisso AE, Eyawo O, Fadhil I, Faraon EJA, Faris PS, Farwati M, Farzadfar F, Fernandes E, Fernandez Prendes C, Ferrara P, Filip I, Fischer F, Flood D, Fukumoto T, Gad MM, Gaidhane S, Ganji M, Garg J, Gebre AK, Gebregiorgis BG, Gebregzabiher KZ, Gebremeskel GG, Getacher L, Obsa AG, Ghajar A, Ghashghaee A, Ghith N, Giampaoli S, Gilani SA, Gill PS, Gillum RF, Glushkova EV, Gnedovskaya EV, Golechha M, Gonfa KB, Goudarzian AH, Goulart AC, Guadamuz JS, Guha A, Guo Y, Gupta R, Hachinski V, Hafezi-Nejad N, Haile TG, Hamadeh RR, Hamidi S, Hankey GJ, Hargono A, Hartono RK, Hashemian M, Hashi A, Hassan S, Hassen HY, Havmoeller RJ, Hay SI, Hayat K, Heidari G, Herteliu C, Holla R, Hosseini M, Hosseinzadeh M, Hostiuc M, Hostiuc S, Househ M, Huang J, Humayun A, Iavicoli I, Ibeneme CU, Ibitoye SE, Ilesanmi OS, Ilic IM, Ilic MD, Iqbal U, Irvani SSN, Islam SMS, Islam RM, Iso H, Iwagami M, Jain V, Javaheri T, Jayapal SK, Jayaram S, Jayawardena R, Jeemon P, Jha RP, Jonas JB, Jonnagaddala J, Joukar F, Jozwiak JJ, Jürisson M, Kabir A, Kahlon T, Kalani R, Kalhor R, Kamath A, Kamel I, Kandel H, Kandel A, Karch A, Kasa AS, Katoto PDMC, Kayode GA, Khader YS, Khammarnia M, Khan MS, Khan MN, Khan M, Khan EA, Khatab K, Kibria GMA, Kim YJ, Kim GR, Kimokoti RW, Kisa S, Kisa A, Kivimäki M, Kolte D, Koolivand A, Korshunov VA, Koulmane Laxminarayana SL, Koyanagi A, Krishan K, Krishnamoorthy V, Kuate Defo B, Kucuk Bicer B, Kulkarni V, Kumar GA, Kumar N, Kurmi OP, Kusuma D, Kwan GF, la Vecchia C, Lacey B, Lallukka T, Lan Q, Lasrado S, Lassi ZS, Lauriola P, Lawrence WR, Laxmaiah A, LeGrand KE, Li MC, Li B, Li S, Lim SS, Lim LL, Lin H, Lin Z, Lin RT, Liu X, Lopez AD, Lorkowski S, Lotufo PA, Lugo A, M NK, Madotto F, Mahmoudi M, Majeed A, Malekzadeh R, Malik AA, Mamun AA, Manafi N, Mansournia MA, Mantovani LG, Martini S, Mathur MR, Mazzaglia G, Mehata S, Mehndiratta MM, Meier T, Menezes RG, Meretoja A, Mestrovic T, Miazgowski B, Miazgowski T, Michalek IM, Miller TR, Mirrakhimov EM, Mirzaei H, Moazen B, Moghadaszadeh M, Mohammad Y, Mohammad DK, Mohammed S, Mohammed MA, Mokhayeri Y, Molokhia M, Montasir AA, Moradi G, Moradzadeh R, Moraga P, Morawska L, Moreno Velásquez I, Morze J, Mubarik S, Muruet W, Musa KI, Nagarajan AJ, Nalini M, Nangia V, Naqvi AA, Narasimha Swamy S, Nascimento BR, Nayak VC, Nazari J, Nazarzadeh M, Negoi RI, Neupane Kandel S, Nguyen HLT, Nixon MR, Norrving B, Noubiap JJ, Nouthe BE, Nowak C, Odukoya OO, Ogbo FA, Olagunju AT, Orru H, Ortiz A, Ostroff SM, Padubidri JR, Palladino R, Pana A, Panda-Jonas S, Parekh U, Park EC, Parvizi M, Pashazadeh Kan F, Patel UK, Pathak M, Paudel R, Pepito VCF, Perianayagam A, Perico N, Pham HQ, Pilgrim T, Piradov MA, Pishgar F, Podder V, Polibin RV, Pourshams A, Pribadi DRA, Rabiee N, Rabiee M, Radfar A, Rafiei A, Rahim F, Rahimi-Movaghar V, Ur Rahman MH, Rahman MA, Rahmani AM, Rakovac I, Ram P, Ramalingam S, Rana J, Ranasinghe P, Rao SJ, Rathi P, Rawal L, Rawasia WF, Rawassizadeh R, Remuzzi G, Renzaho AMN, Rezapour A, Riahi SM, Roberts-Thomson RL, Roever L, Rohloff P, Romoli M, Roshandel G, Rwegerera GM, Saadatagah S, Saber-Ayad MM, Sabour S, Sacco S, Sadeghi M, Saeedi Moghaddam S, Safari S, Sahebkar A, Salehi S, Salimzadeh H, Samaei M, Samy AM, Santos IS, Santric-Milicevic MM, Sarrafzadegan N, Sarveazad A, Sathish T, Sawhney M, Saylan M, Schmidt MI, Schutte AE, Senthilkumaran S, Sepanlou SG, Sha F, Shahabi S, Shahid I, Shaikh MA, Shamali M, Shamsizadeh M, Shawon MSR, Sheikh A, Shigematsu M, Shin MJ, Shin JI, Shiri R, Shiue I, Shuval K, Siabani S, Siddiqi TJ, Silva DAS, Singh JA, Mtech AS, Skryabin VY, Skryabina AA, Soheili A, Spurlock EE, Stockfelt L, Stortecky S, Stranges S, Suliankatchi Abdulkader R, Tadbiri H, Tadesse EG, Tadesse DB, Tajdini M, Tariqujjaman M, Teklehaimanot BF, Temsah MH, Tesema AK, Thakur B, Thankappan KR, Thapar R, Thrift AG, Timalsina B, Tonelli M, Touvier M, Tovani-Palone MR, Tripathi A, Tripathy JP, Truelsen TC, Tsegay GM, Tsegaye GW, Tsilimparis N, Tusa BS, Tyrovolas S, Umapathi KK, Unim B, Unnikrishnan B, Usman MS, Vaduganathan M, Valdez PR, Vasankari TJ, Velazquez DZ, Venketasubramanian N, Vu GT, Vujcic IS, Waheed Y, Wang Y, Wang F, Wei J, Weintraub RG, Weldemariam AH, Westerman R, Winkler AS, Wiysonge CS, Wolfe CDA, Wubishet BL, Xu G, Yadollahpour A, Yamagishi K, Yan LL, Yandrapalli S, Yano Y, Yatsuya H, Yeheyis TY, Yeshaw Y, Yilgwan CS, Yonemoto N, Yu C, Yusefzadeh H, Zachariah G, Zaman SB, Zaman MS, Zamanian M, Zand R, Zandifar A, Zarghi A, Zastrozhin MS, Zastrozhina A, Zhang ZJ, Zhang Y, Zhang W, Zhong C, Zou Z, Zuniga YMH, Murray CJL, Fuster V (2020) Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 76(25):2982–302110.1016/j.jacc.2020.11.010 ↗

39. Shao M, Yang W, Han G (2017) Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles. Int J Nanomedicine. 12:7121–713010.2147/IJN.S141549 ↗

40. Sharma G, She ZG, Valenta DT, Stallcup WB, Smith JW (2010) Targeting of macrophage foam cells in atherosclerotic plaque using oligonucleotide-functionalized nanoparticles. Nano Life. 1(3-4):207–21410.1142/S1793984410000183 ↗

41. Sharma AK, Kumar A, Taneja G, Nagaich U, Deep A, Datusalia AK, Rajput SK (2018) Combined and individual strategy of exercise generated preconditioning and low dose copper nanoparticles serve as superlative approach to ameliorate ISO-induced myocardial infarction in rats. Pharmacol Rep. 70(4):789–79510.1016/j.pharep.2018.02.023 ↗

42. Sluimer JC, Daemen MJ (2009) Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol. 218(1):7–2910.1002/path.2518 ↗

43. Somasuntharam I, Boopathy AV, Khan RS, Martinez MD, Brown ME, Murthy N, Davis ME (2013) Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarction. Biomaterials. 34(31):7790–779810.1016/j.biomaterials.2013.06.051 ↗

44. Thirupathi G, Swetha E, Narendar D (2017) Role of isradipine loaded solid lipid nanoparticles on the pharmacodynamic effect in rats. Drug Res (Stuttg). 67(3):163–169

45. Tuerdi N, Xu L, Zhu B, Chen C, Cao Y, Wang Y, Zhang Q, Li Z, Qi R (2016) Preventive effects of simvastatin nanoliposome on isoproterenol-induced cardiac remodeling in mice. Nanomedicine. 12(7):1899–190710.1016/j.nano.2016.05.002 ↗

46. Vicencio JM, Yellon DM, Sivaraman V, Das D, Boi-Doku C, Arjun S, Zheng Y, Riquelme JA, Kearney J, Sharma V, Multhoff G, Hall AR, Davidson SM (2015) Plasma exosomes protect the myocardium from ischemia-reperfusion injury. J Am Coll Cardiol. 65(15):1525–153610.1016/j.jacc.2015.02.026 ↗

47. Xue HY, Liu S, Wong HL (2014) Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine (Lond). 9(2):295–31210.2217/nnm.13.204 ↗

48. Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, Tarin C, Mas S, Ortiz A, Egido J (2011) Animal models of cardiovascular diseases. J Biomed Biotechnol 2011:49784110.1155/2011/497841 ↗

49. Zhang JS (2005) F L, L H. Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev. 57(5):689–69810.1016/j.addr.2004.12.004 ↗

50. Zhang XQ, Even-Or O, Xu X, van Rosmalen M, Lim L, Gadde S, Farokhzad OC, Fisher EA (2015) Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis. Adv Healthc Mater. 4(2):228–23610.1002/adhm.201400337 ↗

51. Zhang J, Xue Y, Ni Y, Ning F, Shang L, Ma A (2018) Size dependent effects of gold nanoparticles in ISO-induced hyperthyroid rats. Sci Rep. 8(1):1096010.1038/s41598-018-27934-9 ↗